Congcong Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2392118/publications.pdf

Version: 2024-02-01

16 papers	1,877 citations	623734 14 h-index	996975 15 g-index
16 all docs	16 docs citations	16 times ranked	2346 citing authors

#	Article	IF	Citations
1	ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. Journal of the National Cancer Institute, 2016, 108, .	6.3	282
2	Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor. Molecular Therapy, 2015, 23, 330-338.	8.2	274
3	Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Frontiers in Immunology, 2017, 8, 533.	4.8	232
4	3D model for <scp>CAR</scp> â€mediated cytotoxicity using patientâ€derived colorectal cancer organoids. EMBO Journal, 2019, 38, .	7.8	200
5	Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. OncoImmunology, 2016, 5, e1119354.	4.6	151
6	Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy, 2017, 19, 235-249.	0.7	142
7	CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. Frontiers in Immunology, 2019, 10, 2683.	4.8	142
8	A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies. Journal of Immunological Methods, 2007, 318, 113-124.	1.4	110
9	Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunology, Immunotherapy, 2018, 67, 25-38.	4.2	84
10	Delivery of antibodies to the cytosol. MAbs, 2014, 6, 943-956.	5.2	67
11	â€œUniCARâ€modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Scientific Reports, 2020, 10, 2141.	3.3	62
12	Analysis of IgG heavy chain to light chain ratio with mutant Encephalomyocarditis virus internal ribosome entry site. Protein Engineering, Design and Selection, 2007, 20, 491-496.	2.1	47
13	Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity. , 2021, 9, e002980.		28
14	Suppression of p75 Neurotrophin Receptor Surface Expression with Intrabodies Influences Bcl-xL mRNA Expression and Neurite Outgrowth in PC12 Cells. PLoS ONE, 2012, 7, e30684.	2.5	25
15	Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology. BioDrugs, 2020, 34, 435-462.	4.6	24
16	Evaluating the Delivery of Proteins to the Cytosol of Mammalian Cells. Methods in Molecular Biology, 2017, 1513, 201-208.	0.9	7